This initiative would complement existing NIMH-participating initiatives that aim to support research at multiple stages in the drug development pipeline, including assay development and screening (PAR-17-438); optimization and early preclinical discovery (PAR-19-146, PAR-19-147); and, the transition from early discovery to Phase I Clinical Trials (PAR-18-541, PAR-18-546).